The safety and efficacy of radiofrequency ablation and cryoablation in patients with atrial fibrillation (AF) under anticoagulant therapy with apixaba
Not Applicable
- Conditions
- atrial fibrillation
- Registration Number
- JPRN-UMIN000018901
- Lead Sponsor
- Tokyo Medical and Dental University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 260
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with a history of hypersensitivity to the components of apixaban. Patients with clinically significant bleeding symptoms. Patients with blood clotting defect and liver disease at clinically significant bleeding risk.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Composite of major bleedings and thromboembolism during perioperative period and within 4 weeks after the surgery.
- Secondary Outcome Measures
Name Time Method Recurrence of AF during the follow-up period (because the presence or absence of recurrence may be associated with the development of embolic events), non-major bleeding, pericardial effusions not requiring drainage.